Peculiarities of hormonal homeostasis in perimenopausal and postmenopausal women with menopausal disorders


  • О.V. Vaskiv National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • А.P. Grigorenko National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • О.G. Horbatiuk National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • A.S. Shatkovska National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • А.N. Binkovska National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: hormonal homeostasis, perimenopause, postmenopause, menopausal disorders.

Abstract

According to WHO, now on the planet 46% of women are over the age of 45 years, among women in Ukraine – this is almost half (13.2 million). Of these, 46-68% suffer from climacteric syndrome. An increase in the duration of a healthy life and prolongation of the age of working capacity acquire not only medical, but also socio-economic significance, both in Ukraine and in other European countries. Therefore, the aim of the study was a comprehensive (involving pituitary, ovarian, adrenal and thyroid hormones) hormonal examination of women of peri- and postmenopausal age with menopause syndrome to identify the most likely hormonal predictors of this pathology. For this purpose, 64 women of perimenopausal and postmenopausal age with menopause and 42 healthy women of the same age categories had a study of the concentration of pituitary (LH, FSH, prolactin), ovarian hormones (estradiol, progesterone, testosterone), thyroid hormones (TSH, triiodothyronine (T3), thyroxine (T4)) and adrenal glands (DHEA-s, cortisol) in blood plasma. Hormones were determined using a set of test systems from “Immunotech” (Czech Republic-France) using the radio-immune method. Comparisons of the quantitative data of the two related groups (before and after treatment) were made using Wilcoxon signed rank test. When differences were detected, pairwise group comparisons were performed using the Mann-Whitney test. In women of perimenopausal and postmenopausal age with menopause syndrome, compared with healthy women of the same age groups, a significant increase in gonadotropin levels (LH by 3.7 and 3.0 times, respectively; FSH by 1.6 and 1.9 times) and a decrease indicator of prolactin in 1.5 and 1.2 times; estradiol 1.2 and 2.2 times and testosterone 2.9 and 2.4 times. A significant decrease in progesterone by 1.9 times occurred only in the group of postmenopausal women with menopause syndrome. In women of perimenopausal and postmenopausal age of the main group, a significant decrease was found in comparison with the control of DHEA-s levels by 1.3 times and 2.2 times, respectively; cortisol 1.2 and 2.0 times; TSH is 2.6 times and 2.0 times, respectively, however, thyroxine tended to increase (the probability p<0.05 was valid only for women of perimenopausal age). Thus, in postmenopausal women with menopausal syndrome, hormonal imbalance is more pronounced, indicating a deep atrophy of hormone-dependent tissue receptors and, as a result, a deepening of involutive processes.

References

[1] Baber, R. J., Panay, N., Fenton, A., & the IMS Writing Group (2016). IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric, 19(2), 109-150. http://dx.doi.org/10.3109/13697137.2015.1129166

[2] Beck, V., Unterrieder, E., Krenn, L., Kubelka, W., & Jungbauer, A. (2003). Comparison of hormonal activity (estrogen, androgen, and progestin) of standardized plant extract for large scale use in hormone replacement therapy. Journal of Steroid Biochemistry & Molecular Biology, 1831, 1-10. doi: 10.1016/s0960-0760(03)00034-7

[3] Grigorenco, A. P., Shymanska-Horbatyuk, O. G., Shatkovska, N. S., & Garbuziuk, V. V. (2013). Hormonal homeostasis in women with prolapse of the pelvic organs. Collection of scientific works of the Association of obstetricians and gynecologist of Ukraine. Kyiv: Poligraf plus.

[4] Horbatiuk, O. H. (2017). Method for correction of climacteric disorders in women of peri- and postmenopausal age. Medical practice, 5-6, 121-125. https://vrachebnoedelo.com/index.php/journal/issue/view/42/5-6-2017-PDF

[5] Horbatiuk, O. H., Shatkovska, А. S., & Hryhorenko, А. P. (2016). Menopausal syndrome: a training manual for physicians. Vinnitsa. VNMU n.a. Pirogov.

[6] Horbatiuk, O., Binkovska, A., Herych O., Ropotan, A., Zhylko, N., Mandziy, I., & Buleza, I. (2017). Using micronized progesterone for treatment of premenopausal age women suffering from severe premenstrual syndrome. Current Issues in Pharmacy and Medical Sciences, 30(3), 138-141. doi: 10.1515/cipms-2017-0025

[7] Horbatiuk, О. H., Hryhorenko, А. P., Shatkovska, А. S., Binkovska, А. M., Onyshko, V. Yu., & Gerich, О. Kh. (2017). Optimization of the vegetative-forensic and neuropsychiatric destruction of the clinical syndrome. Zaporizhzhya medical journal, 19(4), 482-486. doi: https://doi.org/10.14739/2310-1210.2017.4.105110

[8] Kochetov, A. G., Lianh, O. V., Masenko, V. P., Zhyrov, I. V., Nakonechnykov, S. N., & Tereshchenko, S. N. (2012). Methods of statistical processing of medical data: guidelines. Moscow: Ministry of Health of the Russian Federation, Russian Cardiology Research and Production Complex. https://www.fedlab.ru/upload/medialibrary/e05/_.pdf

[9] Kyrianov, B. F., & Tokmachjov, M. S. (2009). Mathematical Models in Health Care: A Tutorial. Veliky Novgorod: NovSU Yaroslav the Wise. ISBN: 978-589896-357-6

[10] Manukhyn, I. B., Tumylovych, L. G., Hevorkian, M. A., & Manukhyna, E. I. (2016). Gynecological endocrinology. Clinical Lectures: A Guide. (4th ed., Revised). Moscow: GEOTAR - Media.

[11] Namiki, T., Sato, H., Matsumoto, Y., Kakikura, H., Ueno, K., Chino, A., ... & Kihara, M. (2014). Identification of a predictive biomarker for the beneficial effect of keishibukuryogan, a Kampo (Japanese traditional) medicine, on patients with climacteric syndrome. Evidence-Based Complementary and Alternative Medicine, 2014, 962109. doi: 10.1155/2014/962109

[12] North American Menopause Society. (2013). Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause, 20(9), 888-902. doi: 10.1097/GME.0b013e3182a122c2

[13] Nyirjesy, P. (2007). Postmenopausal vaginitis. Current Infectious Disease Reports, 9(6), 480-484. doi: 10.1007/s11908-007-0073-5

[14] Palacios, S. (2009). Managing urogenital atrophy. Maturitas, 63(4), 315-318. doi: 10.1016/j.maturitas.2009.04.009

[15] Pereira, R. I., Casey, B. A., Swibas, T. A., Erickson, C. B., Wolfe, P., & Van Pelt, R. E. (2015). Timing of estradiol treatment after menopause may determine benefit or harm to insulin action. The Journal of Clinical Endocrinology & Metabolism, 100(12), 4456-4462. doi: 10.1210/jc.2015-3084

[16] Scott, J. R., Gibbs, R. S., Karlan, B. Y., & Haney, A. F. (Ed). (2003). Danforth’s Obstetrics and Gynecology (9th edition). Philadelphia – New York: Lippincott Williams & Wilkins Publishers. ISBN 10: 0781737303

[17] Studd, J. (2012). Spotlight on severe premenstrual syndrome and bipolar disorder: a frequent tragic confusion. Climacteric, 14, 602. doi: 10.1258/mi.2012.012018

[18] Tatarchuk, T. F., Avramenko, N. V., Bulavenko, O. V., Habal, V. A., Burlaka, O. V., Hanzhyi, I. Yu., ... & Hiulmamedova, I. D. (2016). National consensus on the management of patients in menopause. Reproductive endocrinology, 27(1), 8-25. https://doi.org/10.18370/2309-4117.2016.27.8-25

[19] Verner, I. E. (2019). Regions of Ukraine 2019: Stat. Collection of the State Statistics Committee of Ukraine. http://www.ukrstat.gov.ua/druk/publicat/kat_u/2019/zb/12/zb_ru1ch2019.pdf

[20] Weiser, M. J., Foradori, C. D., & Handa, R. J. (2008). Estrogen receptor beta in the brain: from form to function. Brain Research Reviews, 57, 309-320. doi: 10.1016/j.brainresrev.2007.05.013
Published
2019-05-05
How to Cite
VaskivО., GrigorenkoА., HorbatiukО., Shatkovska, A., & BinkovskaА. (2019). Peculiarities of hormonal homeostasis in perimenopausal and postmenopausal women with menopausal disorders. Biomedical and Biosocial Anthropology, (35), 43-47. https://doi.org/https://doi.org/10.31393/bba35-2019-07